Data Sheet 4_A lactylation-ferroptosis cross-talk gene signature predicts hepatocellular carcinoma prognosis and reveals STMN1/PRDX1 as therapeutic targets.zip by Jiali Meng (4799928)

“…Metabolic reprogramming and ferroptosis resistance play critical roles in HCC development and progression.…”

Data Sheet 2_A lactylation-ferroptosis cross-talk gene signature predicts hepatocellular carcinoma prognosis and reveals STMN1/PRDX1 as therapeutic targets.zip by Jiali Meng (4799928)

“…Metabolic reprogramming and ferroptosis resistance play critical roles in HCC development and progression.…”

Data Sheet 5_A lactylation-ferroptosis cross-talk gene signature predicts hepatocellular carcinoma prognosis and reveals STMN1/PRDX1 as therapeutic targets.zip by Jiali Meng (4799928)

“…Metabolic reprogramming and ferroptosis resistance play critical roles in HCC development and progression.…”

Data Sheet 3_A lactylation-ferroptosis cross-talk gene signature predicts hepatocellular carcinoma prognosis and reveals STMN1/PRDX1 as therapeutic targets.zip by Jiali Meng (4799928)

“…Metabolic reprogramming and ferroptosis resistance play critical roles in HCC development and progression.…”

Data Sheet 6_A lactylation-ferroptosis cross-talk gene signature predicts hepatocellular carcinoma prognosis and reveals STMN1/PRDX1 as therapeutic targets.zip by Jiali Meng (4799928)

“…Metabolic reprogramming and ferroptosis resistance play critical roles in HCC development and progression.…”

Data Sheet 1_A lactylation-ferroptosis cross-talk gene signature predicts hepatocellular carcinoma prognosis and reveals STMN1/PRDX1 as therapeutic targets.zip by Jiali Meng (4799928)

“…Metabolic reprogramming and ferroptosis resistance play critical roles in HCC development and progression.…”

Table 1_A lactylation-ferroptosis cross-talk gene signature predicts hepatocellular carcinoma prognosis and reveals STMN1/PRDX1 as therapeutic targets.doc by Jiali Meng (4799928)

“…Metabolic reprogramming and ferroptosis resistance play critical roles in HCC development and progression.…”

Data Sheet 1_Bacteriocin KvarM versus conventional antibiotics: comparative effectiveness in treating Klebsiella pneumoniae infections in murine intestinal models.pdf by Indre Karaliute (20906606)

“…Furthermore, microbiome analysis of the gut microbiota revealed that KvarM therapy showed no significant changes in microbial composition compared with commensal microbiota composition, whereas administration of ciprofloxacin led to a significant decrease in microbial diversity.…”

<b>Effects of obesity and hyperglycemia on postprandial insulin-mediated and non-insulin-mediated glucose disposal</b> by Bettina Mittendorfer (88840)

“…ILT in people with obesity and T2D increased IMGD and decreased NIMGD.</p><p dir="ltr">Conclusion. NIMGD is a major mechanism of postprandial TGD in people with insulin resistance and inadequate insulin secretion.…”

Supplementary Material for: The Effectiveness of a Hospital-Based Antimicrobial Stewardship Program: A Three-Year Observational Study by figshare admin karger (2628495)

“…Indicators included antibiotic use defined dailydoses (DDD), days of therapy (DOT), policy compliance, resistance rates, and clinical outcomes. …”

Image 1_Emapalumab for severe cytokine release syndrome in solid tumor CAR-T: a case report.tif by Tyler Ruemmele (20972594)

“…The hemodynamic improvement was associated with a decrease in IFN-γ and CXCL10 levels but no other cytokines. …”

Supplementary file 1_The action of ginsenoside Rg1 in patients with carotid atherosclerosis: a controlled clinical trial.docx by Xu Fang (450501)

“…It improved quality of life, decreased specific inflammatory markers, and enhanced blood pressure control and Insulin Resistance (IR). …”

Table 1_PARP inhibition increases sensitivity to cisplatin in non-small-cell lung carcinoma via the induction of TET-dependent hydroxymethylation.xlsx by Nevena Grdović (394542)

“…The use of PARPi in clinical settings could increase the number of patients enriched in 5hmC, who might benefit from platinum-based therapy. Additionally, targeting epigenetic marks could provide a molecular basis for personalized cancer therapy directed to overcome tumor resistance.…”

Data Sheet 1_PARP inhibition increases sensitivity to cisplatin in non-small-cell lung carcinoma via the induction of TET-dependent hydroxymethylation.pdf by Nevena Grdović (394542)

“…The use of PARPi in clinical settings could increase the number of patients enriched in 5hmC, who might benefit from platinum-based therapy. Additionally, targeting epigenetic marks could provide a molecular basis for personalized cancer therapy directed to overcome tumor resistance.…”

Data Sheet 1_20(S)-protopanaxadiol inhibits proliferation and induces apoptosis of acute myeloid leukemia cells via targeting Bcl-XL and MCL-1.pdf by Meng Xu (62933)

“…Despite advances in treatment such as targeted therapies, patient outcomes remain unsatisfactory due to adverse drug reactions, susceptibility to drug resistance, and high recurrence rates. …”

Image 1_20(S)-protopanaxadiol inhibits proliferation and induces apoptosis of acute myeloid leukemia cells via targeting Bcl-XL and MCL-1.jpg by Meng Xu (62933)

“…Despite advances in treatment such as targeted therapies, patient outcomes remain unsatisfactory due to adverse drug reactions, susceptibility to drug resistance, and high recurrence rates. …”

Image 4_ZKSCAN3 promotes ovarian cancer cell proliferation by increasing HSPB1 expression.pdf by Qian Ke (9164990)

“…However, resistance develops in most ovarian cancer patients. …”

Table 1_ZKSCAN3 promotes ovarian cancer cell proliferation by increasing HSPB1 expression.docx by Qian Ke (9164990)

“…However, resistance develops in most ovarian cancer patients. …”

Image 3_ZKSCAN3 promotes ovarian cancer cell proliferation by increasing HSPB1 expression.pdf by Qian Ke (9164990)

“…However, resistance develops in most ovarian cancer patients. …”

Image 1_ZKSCAN3 promotes ovarian cancer cell proliferation by increasing HSPB1 expression.pdf by Qian Ke (9164990)

“…However, resistance develops in most ovarian cancer patients. …”